8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                             Current Report Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported) February 13, 2003

                             BOSTON BIOMEDICA, INC.
              ----------------------------------------------------
             (Exact Name Of Registrant As Specified In Its Charter)

                                  MASSACHUSETTS
                  --------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

           0-21615                                    04-2652826
    ----------------------                ---------------------------------
   (Commission File Number)              (I.R.S.Employer Identification No.)

  375 West Street, West Bridgewater, MA                           02379
  --------------------------------------                        --------
 (Address of Principal Executive Offices)                      (Zip Code)

                                 (508) 580-1900
               --------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)

                                       N/A
           -----------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)







ITEM 5.           OTHER EVENTS
- ------

On February 14, 2003, Boston Biomedica,  Inc. announced that the Company's Board
of  Directors  had  terminated  Richard  T.  Schumacher  as  Chairman  and Chief
Executive  Officer.  A copy of the press  release  issued on  February  14, 2003
regarding the termination of Mr. Schumacher is filed as Exhibit 99.1.


ITEM 7.           EXHIBITS
- ------

Exhibit Number                  Description
- --------------                  -----------
99.1                            Press Release dated February 14, 2003




                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: February 24, 2003                 BOSTON BIOMEDICA, INC.



                               By:       /s/ Kevin W. Quinlan
                                         --------------------------------------
                                         Kevin W. Quinlan,
                                         President and Chief Operating Officer
                                         and Treasurer







                                INDEX TO EXHIBITS

  Exhibit
   Number                           Description
- -----------   ------------------------------------------------------


   99.1       Press Release dated February 14, 2003

EX-99

FOR IMMEDIATE RELEASE

Investor Contact:

Kevin W. Quinlan, President & COO
Boston Biomedica, Inc.
508-580-1900 (T)

BOSTON BIOMEDICA ANNOUNCES TERMINATION OF CEO

WEST BRIDGEWATER, MA -- February 14, 2003 -- Boston Biomedica, Inc.
(NASDAQ: BBII) announced that the Companys Board of Directors has
terminated Richard T. Schumacher as Chairman and Chief Executive Officer,
effective immediately, for personal financial reasons.  He remains a Director
of the Company.

William A. Wilson, a Director, was named Chairman of the Board.  Kevin Quinlan,
President and Chief Operating Officer, will continue leading day to day
operations.  A special committee of the Board of Directors has been appointed
to seek a replacement for Mr. Schumacher and to oversee the transition.

Ric Schumacher did an outstanding job of building the Company he founded in
1986 into a leading supplier of quality control products and services for the
life sciences industry said Kevin Quinlan, President and COO.  Thanks to Ric,
Boston Biomedica is an industry leader with valuable customers, assets and
employees.  We are grateful for his vision and his many years of service.

About Boston Biomedica, Inc.

Boston Biomedica, Inc. provides products and services to the diagnostics and
life sciences industries to evaluate, monitor, and ensure the quality of
infectious disease test results, to improve the preparation of specimens for
genomic/proteomic testing, and to safely store and retrieve rare and valuable
biological specimens.  We also manufacture biological reagents used in test
kits and provide a broad range of routine and esoteric research services to
governments and industry.  BBI has offices in three states, and conducts
research in new applications for our patented Pressure Cycling Technology(PCT).
In 2000, we launched Panacos Pharmaceuticals, and the Company maintains a
significant passive investment in this novel antiviral drug development company.


Statements contained in this news release that state the Companys or
managements intentions, hopes, beliefs, expectations or predictions of the
future are forward-looking statements.  It is important to note that the
Companys actual results could differ materially from those projected in such
forward-looking statements.  Factors that could cause actual results to differ
from those projected include the possibility that the Companys revenues may be
lower than expected and expenses may be higher than expected with the result
that the Company may need additional capital for its operations.  Further,
should additional financing become necessary or desirable, the Company may not
be able to secure such additional financing upon acceptable terms.  Since the
Company has not yet commenced its search for a replacement Chief Executive
Officer, there can be no assurance that the Company will find a suitable
replacement upon acceptable terms. Additional information concerning factors
that could cause actual results to differ materially from those in the
forward-looking statements is contained from time to time in the Company's SEC
filings, including but not limited to the Company's Annual Report on Form 10-K
for the year ended December 31, 2001, and the Companys quarterly reports on
Form 10-Q for the three months ended March 31, June 30, and September 30, 2002.
Copies of these documents may be obtained by contacting the Company or the SEC.

######

Visit us at our website http://www.bbii.com
Please email us at IR@bbii.com if you prefer to receive future announcements
electronically